| Project/Area Number |
21790071
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Kobe Pharmaceutical University |
|---|
Principal Investigator |
KONISHI Morichika Kobe Pharmaceutical University, 薬学部, 准教授 (00322165)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ITOH Nobuyuki 京都大学, 薬学研究科・遺伝子薬学分野 (10110610)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2009: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | FGF / 白色脂肪細胞 / エネルギー代謝 / 肥満症 / 白色脂肪組織 / Fgf / ケトン食 / インスリン感受性 / Lp1 / 脂肪組織 / 脂肪分解 / 絶食 / 脂質代謝 |
|---|
| Research Abstract |
The pharmacological effects suggest that liver-derived Fgf21 physiologically regulates the function of white adipose tissue and systemic energy metabolism. To elucidate the physiological roles of Fgf21, we analyzed Fgf21 knockout mice generated by targeted disruption under several conditions including fasting. Our results indicate that Fgf21 regulates lipolysis in white adipose tissue and systemic insulin sensitivity in response to the metabolic state.
|
